Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Pant delivers keynote address at National Conclave on “Augmented Zoonotic Diseases Surveillance at Human – Wildlife Interface”
National Health Authority (NHA) to host the two-day Arogya Manthan event in New Delhi
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
The Government of India continues to prioritise initiatives aimed at enhancing the accessibility and equity of health services
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
With India supplying around 60% of the world's vaccine needs and 20-22% of generic exports, the country is dedicated to providing affordable, high-quality drugs and contribute to global accessibility
Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB
Subscribe To Our Newsletter & Stay Updated
